Substrate
Topic

preclinical-research

1 stories related to this topic, newest first.

Akari Therapeutics Stock Falls After 255 Percent Weekly Gainmanilatimes.net
finance3 days agoDeveloping

Akari Therapeutics Stock Falls After 255 Percent Weekly Gain

Akari Therapeutics PLC shares declined on Tuesday following a 255 percent surge late last week. The movement came after the company reported preclinical results for its AKTX-101 asset in KRAS-mutated pancreatic cancer models.

Benzinga
1 source